文献速递淋巴瘤造血干细胞移植与细胞治疗

大B细胞淋巴瘤患者接受阿基仑赛治疗后致死性迟发性CAR-T细胞介导脑炎

Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

本文报道一例复发难治性大B细胞淋巴瘤患者在接受阿基仑赛(axi-cel)输注9个月后出现进行性中枢神经毒性,尽管给予全身及鞘内免疫抑制治疗,仍在5个月内死亡。脑脊液检出高CAR-T细胞DNA拷贝数及IL-1、IL-6升高,尸检见CAR-T细胞脑浸润,提示CAR-T细胞参与致病。

要点

  • axi-cel治疗后迟发性神经毒性可发生于输注后9个月,远超常规4周监测窗口。
  • 严重ICANS在axi-cel治疗患者中发生率可达30%至40%,通常对激素反应良好。
  • 脑脊液CAR-T细胞DNA拷贝数升高及IL-1、IL-6升高可能提示迟发神经毒性。

核心结论

  • axi-cel输注后9个月可发生致死性迟发性CAR-T细胞介导脑炎,提示需对该脆弱人群持续监测迟发毒性。

研究设计与样本

  • 单例病例报告:一例复发难治性大B细胞淋巴瘤患者,既往接受过异基因造血干细胞移植,接受axi-cel输注。

主要发现

  • 患者在axi-cel输注9个月后出现进行性中枢神经毒性,尽管给予广泛全身及鞘内免疫抑制,神经功能仍不可逆恶化,5个月内死亡。
  • 症状出现时脑脊液检出高CAR-T细胞DNA拷贝数及IL-1、IL-6水平升高。
  • 尸检观察到CAR-T细胞脑浸润,提示CAR-T细胞在发病中起主要致病作用。

关键数值与推荐

  • 严重ICANS在axi-cel治疗患者中发生率可达30%至40%,通常发生于给药后4周内,且对激素反应良好。

临床怎么用

  • 对接受CD19定向CAR-T细胞治疗的患者,尤其既往接受过异基因移植者,应警惕迟发性神经毒性并延长监测。

局限性

  • 为单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment with CD19-directed (CAR) T cells has evolved as a standard of care for multiply relapsed or refractory large B-cell lymphoma (r/r LBCL). A common side effect of this treatment is the immune effector cell-associated neurotoxicity syndrome (ICANS). Severe ICANS can occur in up to 30% to 40% of patients treated with axicabtagene-ciloleucel (axi-cel), usually within the first 4 weeks after administration of the dose and usually responding well to steroids. We describe a case of progressive central neurotoxicity occurring 9 months after axi-cel infusion in a patient with r/r LBCL who had undergone a prior allogeneic hematopoietic cell transplant. Despite extensive systemic and intrathecal immunosuppression, neurological deterioration was inexorable and eventually fatal within 5 months. High CAR T-cell DNA copy numbers and elevated levels of interleukin-1 (IL-1) and IL-6 were found in the cerebral spinal fluid as clinical symptoms emerged, and CAR T-cell brain infiltration was observed on autopsy, suggesting that CAR T cells played a major pathogenetic role. This case of unexpected, devastating, late neurotoxicity warrants intensified investigation of neurological off-target effects of CD19-directed CAR T cells and highlights the need for continuous monitoring for late toxicities in this vulnerable patient population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jung S, Greiner J, von Harsdorf S, et al. Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Adv. 2021. PMID: 34496024. doi:10.1182/bloodadvances.2021004889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。